HLA-B and cysteinylated ligands distinguish the antigen presentation landscape of extracellular vesicles

Extracellular vesicles can modulate numerous processes starting from proliferation and tissue restore, to chemo-resistance and mobile differentiation. With the introduction of tissue and immunological focusing on, extracellular vesicles are additionally more and more seen as promising vectors to ship peptide-based most cancers antigens to the human immune system.

Despite the medical relevance and therapeutic potential of such ‘cell-free’ approaches, the pure antigen presentation landscape exported in extracellular vesicles remains to be largely uncharted, as a result of the difficult nature of such preparations and analyses. In the context of therapeutic vesicle manufacturing, a essential analysis of the similarity in vesicular antigen presentation can also be urgently wanted. In this work, we in contrast the HLA-I peptide ligandomes of extracellular vesicles towards that of whole-cells of the similar cell line.

We discovered that extracellular vesicles not solely over-represent HLA-B complexes and peptide ligands, but additionally cysteinylated peptides that will modulate immune responses. Collectively, these findings describe the pre-existing provision of vesicular HLA complexes which may be utilized to hold peptide vaccines, in addition to the propensity for various peptide and post-translationally modified ligands to be introduced, and will define essential concerns in devising novel EV vaccination methods.

Bioorthogonal protein labelling allows the examine of antigen processing of citrullinated and carbamylated auto-antigens

Proteolysis is key to many organic processes. In the immune system, it underpins the activation of the adaptive immune response: degradation of antigenic materials into quick peptides and presentation thereof on main histocompatibility complexes, results in activation of T-cells. This initiates the adaptive immune response towards many pathogens.

Studying proteolysis is tough, as the oft-used polypeptide reporters are vulnerable to proteolytic sequestration themselves. Here we current a brand new method that permits the imaging of antigen proteolysis all through the processing pathway in an unbiased method. By incorporating bioorthogonal functionalities into the protein in place of methionines, antigens will be adopted throughout degradation, while leaving reactive sidechains open to templated and non-templated post-translational modifications, corresponding to citrullination and carbamylation.

Using this method, we adopted and imaged the post-uptake destiny of the generally used antigen ovalbumin, in addition to the post-translationally citrullinated and/or carbamylated auto-antigen vinculin in rheumatoid arthritis, revealing variations in antigen processing and presentation. Zika virus (ZIKV) has emerged as an vital world well being risk, with the not too long ago acquired capability to trigger extreme neurological signs and to persist inside host tissues.

We beforehand demonstrated that an early Asian lineage ZIKV isolate induces a extremely activated CD8 T cell response particular for an immunodominant epitope in the ZIKV envelope protein in wild-type mice. Here we present {that a} modern ZIKV isolate from the Brazilian outbreak severely limits CD8 T cell immunity in mice and blocks era of the immunodominant CD8 T cell response. This is related to a extra sustained an infection that’s cleared between 7- and 14-days post-infection.

Mechanistically, we show that an infection with the Brazilian ZIKV isolate reduces the cross-presentation capability of dendritic cells and fails to completely activate the immunoproteasome. Thus, our examine supplies an isolate-specific mechanism of host immune evasion by one Brazilian ZIKV isolate, which differs from the early Asian lineage isolate and supplies potential perception into viral persistence related to current ZIKV outbreaks.

Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy considerably will increase the efficiency of anti-PD1 checkpoint remedy

Clinical immunotherapy approaches are missing efficacy in the therapy of glioblastoma (GBM). In this examine, we sought to reverse native and systemic GBM-induced immunosuppression utilizing the Helicobacter pylori neutrophil-activating protein (NAP), a potent TLR2 agonist, as an immunostimulatory transgene expressed in an oncolytic measles virus (MV) platform, retargeted to permit viral entry by means of the urokinase-type plasminogen activator receptor (uPAR).

While single-agent murine anti-PD1 therapy or repeat in situ immunization with MV-s-NAP-uPA offered modest survival profit in MV-resistant syngeneic GBM fashions, the mixture therapy led to synergy with a remedy charge of 80% in mice bearing intracranial GL261 tumors and 72% in mice with CT-2A tumors.

Combination NAP-immunovirotherapy induced huge inflow of lymphoid cells in mouse mind, with CD8+ T cell predominance; therapeutic efficacy was CD8+ T cell dependent. Inhibition of the IFN response pathway utilizing the JAK1/JAK2 inhibitor ruxolitinib decreased PD-L1 expression on myeloid-derived suppressor cells in the mind and additional potentiated the therapeutic impact of MV-s-NAP-uPA and anti-PD1.

Our findings help the notion that MV strains armed with bacterial immunostimulatory antigens signify an efficient technique to beat the restricted efficacy of immune checkpoint inhibitor-based therapies in GBM, making a promising translational technique for this deadly mind tumor. One case was optimistic for HLA class I and HLA class II antibodies, whereas 9 circumstances have been optimistic for HLA class II antibodies, and the gene loci have been HLA-DR and/or DQ.

Antibody-mediated rejection (AMR) occurred in 4 of 10 sufferers in the DSA-positive group. Liver perform was irregular in 3 of 38 circumstances in the DSA-negative group. Multivariate evaluation revealed that DSA positivity was an impartial danger issue for liver insufficiency and long-term survival of recipients. In addition, Kaplan-Meier survival evaluation demonstrated that there have been vital variations in the survival of graft recipients between the DSA-positive group and the DSA-negative group (P<0.05).

E. coli antibody
20-ER13	Fitzgerald	1 ml	426 EUR
Description: Rabbit polyclonal E. coli antibody
E. coli antibody
10-E09C	Fitzgerald	100 ug	159.6 EUR
Description: Mouse monoclonal E. coli antibody
E. coli antibody
10-E10A	Fitzgerald	500 ug	591.6 EUR
Description: Mouse monoclonal E. coli antibody
E. coli antibody
10-E10B	Fitzgerald	500 ug	591.6 EUR
Description: Mouse monoclonal E. coli antibody
E. coli antibody
20C-CR1244GP	Fitzgerald	1 ml	561.6 EUR
Description: Goat polyclonal E. coli antibody
E. coli Antibody
abx022970-1ml	Abbexa	1 ml	878.4 EUR
E. coli Antibody
abx022971-1ml	Abbexa	1 ml	1161.6 EUR
E. coli Antibody
abx022975-1ml	Abbexa	1 ml	718.8 EUR
E. coli Antibody
abx022977-1ml	Abbexa	1 ml	811.2 EUR
E. coli Antibody
abx021669-1mg	Abbexa	1 mg	1554 EUR
E. coli Antibody
abx021670-1mg	Abbexa	1 mg	1045.2 EUR
E. coli Antibody
abx021671-02ml	Abbexa	0.2 ml	594 EUR
E. coli Antibody
abx021672-1mg	Abbexa	1 mg	1045.2 EUR
E. coli Antibody
abx021673-1mg	Abbexa	1 mg	1045.2 EUR
Escherichia coli (E. coli) Antibody
abx415692-01mg	Abbexa	0.1 mg	760.8 EUR
Escherichia coli (E. coli) Antibody
abx415712-1ml	Abbexa	1 ml	727.2 EUR
Escherichia coli (E. coli) Antibody
abx411320-1ml	Abbexa	1 ml	610.8 EUR
Rh Blood Group CcEe Antigens (RHCE) Antibody
20-abx211379	Abbexa	493.20 EUR 360.00 EUR	100 ul 50 ul
Rh Blood Group CcEe Antigens (RHCE) Antibody
abx413595-02mg	Abbexa	0.2 mg	678 EUR
Rh Blood Group CcEe Antigens (RHCE) Antibody
abx413596-25ug	Abbexa	25 ug	326.4 EUR
Rh Blood Group CcEe Antigens (RHCE) Antibody
20-abx339688	Abbexa	493.20 EUR 360.00 EUR	100 ul 50 ul
Recombiant (E. coli) Hepatitis C Virus (Hepatitis C Virus (HCV) Antigens-GST fusion protein (mosaic of several antigenic epitopes) (soluble)
HCV36-R	Alpha Diagnostics	each	343.2 EUR
Escherichia coli (E. coli) Antibody (FITC)
abx411322-1ml	Abbexa	1 ml	610.8 EUR
Rabbit Anti-Mycoplasma pneumoniae IgG (all antigens)
MPPN12-A	Alpha Diagnostics	100 ug	578.4 EUR
Escherichia coli (E. coli) Antibody (Biotin)
abx415713-1ml	Abbexa	1 ml	861.6 EUR
Escherichia coli (E. coli) Antibody (Biotin)
abx411321-1ml	Abbexa	1 ml	710.4 EUR
E. coli antibody (HRP)
60-E14	Fitzgerald	1 ml	489.6 EUR
Description: Rabbit polyclonal E. coli antibody (HRP) conjugated
E. coli Antibody (HRP)
abx022972-1ml	Abbexa	1 ml	718.8 EUR
E. coli Antibody (HRP)
abx022978-1ml	Abbexa	1 ml	1053.6 EUR
E. coli antibody (FITC)
60-E13	Fitzgerald	1 ml	453.6 EUR
Description: Rabbit polyclonal E. coli antibody (FITC) conjugated
E. coli Antibody (FITC)
abx022974-1ml	Abbexa	1 ml	777.6 EUR
E. coli antibody (biotin)
60-E13B	Fitzgerald	1 ml	561.6 EUR
Description: Rabbit polyclonal E. coli antibody (biotin) conjugated
E. coli Antibody (Biotin)
abx022976-1ml	Abbexa	1 ml	718.8 EUR
E. coli Antibody (Biotin)
abx022979-1ml	Abbexa	1 ml	886.8 EUR
Anti-Rat Tumor Antigens of Epithelial Origin antibody
STJ16100726	St John's Laboratory	100 µg	1164 EUR
Anti-Rat Tumour Antigens of Epithelial Origin antibody
STJ16100727	St John's Laboratory	100 µg	1164 EUR
E. Coli HCP antibody
20R-EG001	Fitzgerald	1 ml	1004.4 EUR
Description: Goat polyclonal E. Coli HCP antibody
E. coli Skp Antibody
32971-05111	AssayPro	150 ug	313.2 EUR
E. coli GOR Antibody
32540-05111	AssayPro	150 ug	313.2 EUR
E. coli NDK Antibody
32662-05111	AssayPro	150 ug	313.2 EUR
E. coli PPA Antibody
32678-05111	AssayPro	150 ug	313.2 EUR
E. coli glk Antibody
32864-05111	AssayPro	150 ug	313.2 EUR
E. coli O157 antibody
10-1490	Fitzgerald	100 ug	163.2 EUR
Description: Mouse monoclonal E. coli O157 antibody
E. coli O157 antibody
10-1521	Fitzgerald	100 ug	170.4 EUR
Description: Mouse monoclonal E. coli O157 antibody
E. coli O157 antibody
10C-CR1295M3	Fitzgerald	100 ug	470.4 EUR
Description: Mouse monoclonal E. coli O157 antibody
E. coli O157 antibody
10-E12A	Fitzgerald	100 ug	462 EUR
Description: Mouse monoclonal E. coli O157 antibody
E. coli CysH Antibody
30281-05111	AssayPro	150 ug	313.2 EUR
E. coli DnaJ Antibody
32022-05111	AssayPro	150 ug	313.2 EUR
E. coli nanA Antibody
33092-05111	AssayPro	150 ug	313.2 EUR
E. Coli ldhA Antibody
32898-05111	AssayPro	150 ug	313.2 EUR
E. coli deoC Antibody
32936-05111	AssayPro	150 ug	313.2 EUR
E. coli pykF Antibody
32163-05111	AssayPro	150 ug	313.2 EUR
E. coli O157 Antibody
abx021684-1mg	Abbexa	1 mg	1220.4 EUR
E. coli O157 Antibody
abx021685-1mg	Abbexa	1 mg	1195.2 EUR
E. coli O157 Antibody
abx021686-1mg	Abbexa	1 mg	1195.2 EUR
E. coli O157 Antibody
abx021687-1mg	Abbexa	1 mg	1195.2 EUR
E. coli O157 Antibody
abx021688-1mg	Abbexa	1 mg	1128 EUR
E. coli O157 Antibody
abx021689-1mg	Abbexa	1 mg	1195.2 EUR
E. coli O157 Antibody
abx024017-1mg	Abbexa	1 mg	1212 EUR
E. coli O157 Antibody
V3307-100UG	NSJ Bioreagents	100 ug	349.3 EUR
Description: This mAb shows specificity to E. coli O157 in a simple ELISA. Escherichia coli are Gram negative bacterium that are commonly found in the lower intestine of warm-blooded organisms (endotherms). Their serological types are determined in combination with somatic antigens (O group: O1-O173) and flagella antigens (H type: H1-H56). The E. coli that cause intestinal infectious diseases including diarrhea, acute gastritis or colitis are referred to as pathogenic E. coli, which are classified into the following four groups according to differences in the mode of pathogenicity; enteropathogenic E. coli (EPEC), enteroinvasive E. coli (EIEC), enterotoxigenic E. coli (ETEC) and enterohemorrhagic E. coli (EHEC). Although the identification of pathogenic E. coli requires verification of their pathogenicity, pathogenic E. coli often have specific serotypes; therefore, typing of the serogroup and serotype is necessary in screening pathogenic E. coli.
E. coli O157 Antibody
V3307-20UG	NSJ Bioreagents	20 ug	153.3 EUR
Description: This mAb shows specificity to E. coli O157 in a simple ELISA. Escherichia coli are Gram negative bacterium that are commonly found in the lower intestine of warm-blooded organisms (endotherms). Their serological types are determined in combination with somatic antigens (O group: O1-O173) and flagella antigens (H type: H1-H56). The E. coli that cause intestinal infectious diseases including diarrhea, acute gastritis or colitis are referred to as pathogenic E. coli, which are classified into the following four groups according to differences in the mode of pathogenicity; enteropathogenic E. coli (EPEC), enteroinvasive E. coli (EIEC), enterotoxigenic E. coli (ETEC) and enterohemorrhagic E. coli (EHEC). Although the identification of pathogenic E. coli requires verification of their pathogenicity, pathogenic E. coli often have specific serotypes; therefore, typing of the serogroup and serotype is necessary in screening pathogenic E. coli.
E. coli O157 Antibody
V3307SAF-100UG	NSJ Bioreagents	100 ug	349.3 EUR
Description: This mAb shows specificity to E. coli O157 in a simple ELISA. Escherichia coli are Gram negative bacterium that are commonly found in the lower intestine of warm-blooded organisms (endotherms). Their serological types are determined in combination with somatic antigens (O group: O1-O173) and flagella antigens (H type: H1-H56). The E. coli that cause intestinal infectious diseases including diarrhea, acute gastritis or colitis are referred to as pathogenic E. coli, which are classified into the following four groups according to differences in the mode of pathogenicity; enteropathogenic E. coli (EPEC), enteroinvasive E. coli (EIEC), enterotoxigenic E. coli (ETEC) and enterohemorrhagic E. coli (EHEC). Although the identification of pathogenic E. coli requires verification of their pathogenicity, pathogenic E. coli often have specific serotypes; therefore, typing of the serogroup and serotype is necessary in screening pathogenic E. coli.
Inactivated DENV-2 Antigen (E. coli)
VAng-Lsx0084-1mg	Creative Biolabs	1 mg	986.4 EUR
Description: DENV-2, natural antigen from E. coli.
E. coli GroEL Antibody
20012-05011	AssayPro	150 ug	260.4 EUR
E. coli antibody (K99 Pilus)
10-E20A	Fitzgerald	500 ug	591.6 EUR
Description: Mouse monoclonal E. coli antibody (K99 Pilus)
Hepatitis A Virus (HAV) Antigens
HAV17-N-10	Alpha Diagnostics	10 ug	Ask for price
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody
abx140231-01mg	Abbexa	0.1 mg	444 EUR
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody
abx140253-01mg	Abbexa	0.1 mg	444 EUR
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody
abx140254-01mg	Abbexa	0.1 mg	444 EUR
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody
abx140257-01mg	Abbexa	0.1 mg	444 EUR
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody
abx415437-025mg	Abbexa	0.25 mg	678 EUR
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody
abx415449-02mg	Abbexa	0.2 mg	678 EUR
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody
abx413474-02mg	Abbexa	0.2 mg	678 EUR
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody
abx200524-100ug	Abbexa	100 ug	393.6 EUR
Rabbit Anti-E. coli all ag's Polyclonal Antibody
DPAB0123	Creative Diagnostics	1 ml	999.6 EUR
Rabbit Anti-E. coli all ag's Polyclonal Antibody
DPAB0126	Creative Diagnostics	1 ml	1146 EUR
Escherichia coli Serotype O2 (E. coli O2) Antibody
abx411330-02mg	Abbexa	0.2 mg	678 EUR
E. coli O157:H7 antibody
70-XG13	Fitzgerald	1 mg	734.4 EUR
Description: Affinity purified Goat polyclonal E. coli O157:H7 antibody.
E. coli O157 (9.88) Antibody
BNC470207-100	Biotium	100uL	238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF647 conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC470207-500	Biotium	500uL	652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF647 conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC550207-100	Biotium	100uL	238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF555 conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC550207-500	Biotium	500uL	652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF555 conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC400207-100	Biotium	100uL	238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF640R conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC400207-500	Biotium	500uL	652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF640R conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC430207-100	Biotium	100uL	238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF543 conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC430207-500	Biotium	500uL	652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF543 conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC810207-100	Biotium	100uL	238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF680R conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC810207-500	Biotium	500uL	652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF680R conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC610207-100	Biotium	100uL	238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF660R conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC610207-500	Biotium	500uL	652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF660R conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNUM0207-50	Biotium	50uL	474 EUR
Description: Primary antibody against E. coli O157 (9.88), 1mg/mL
E. coli O157 (9.88) Antibody
BNCB0207-100	Biotium	100uL	238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),Biotin conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNCB0207-500	Biotium	500uL	652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),Biotin conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNCP0207-250	Biotium	250uL	459.6 EUR
Description: Primary antibody against E. coli O157 (9.88),PerCP conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNCA0207-250	Biotium	250uL	459.6 EUR
Description: Primary antibody against E. coli O157 (9.88),APC conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNCAP0207-100	Biotium	100uL	238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNCAP0207-500	Biotium	500uL	652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC940207-100	Biotium	100uL	238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF594 conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC940207-500	Biotium	500uL	652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF594 conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNCH0207-100	Biotium	100uL	238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNCH0207-500	Biotium	500uL	652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNUB0207-100	Biotium	100uL	250.8 EUR
Description: Primary antibody against E. coli O157 (9.88), Concentration: 0.2mg/mL
E. coli O157 (9.88) Antibody
BNUB0207-500	Biotium	500uL	549.6 EUR
Description: Primary antibody against E. coli O157 (9.88), Concentration: 0.2mg/mL
E. coli O157:H7 Antibody
abx022980-1mg	Abbexa	1 mg	718.8 EUR
E. coli O157 (9.88) Antibody
BNC040207-100	Biotium	100uL	238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF405S conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC040207-500	Biotium	500uL	652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF405S conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC050207-100	Biotium	100uL	238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF405M conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC050207-500	Biotium	500uL	652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF405M conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC700207-100	Biotium	100uL	238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF770 conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC700207-500	Biotium	500uL	652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF770 conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC800207-100	Biotium	100uL	238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF680 conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC800207-500	Biotium	500uL	652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF680 conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC680207-100	Biotium	100uL	238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF568 conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC680207-500	Biotium	500uL	652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF568 conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC880207-100	Biotium	100uL	238.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF488A conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNC880207-500	Biotium	500uL	652.8 EUR
Description: Primary antibody against E. coli O157 (9.88),CF488A conjugate, Concentration: 0.1mg/mL
E. coli O157 (9.88) Antibody
BNCR0207-250	Biotium	250uL	459.6 EUR
Description: Primary antibody against E. coli O157 (9.88),RPE conjugate, Concentration: 0.1mg/mL
E. coli O157 antibody (FITC)
61C-CR1295M1F	Fitzgerald	100 ug	489.6 EUR
Description: Mouse monoclonal E. coli O157 antibody (FITC)
E. coli O157 antibody (FITC)
61C-CR1295M4F	Fitzgerald	100 ug	561.6 EUR
Description: Mouse monoclonal E. coli O157 antibody (FITC)
Mouse antibody for E. coli
1063	Virostat	100 ug	438.46 EUR
Description: This is Mouse monoclonal FITC conjugated antibody against E coli O157 for WB, ELISA.
E. coli O157 Antibody (FITC)
abx021683-1mg	Abbexa	1 mg	2798.4 EUR
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PE)
abx140294-100tests	Abbexa	100 tests	577.2 EUR
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PE)
abx140305-100tests	Abbexa	100 tests	577.2 EUR
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PE)
abx200526-100tests	Abbexa	100 tests	543.6 EUR
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (APC)
abx140295-100tests	Abbexa	100 tests	577.2 EUR
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (APC)
abx140306-100tests	Abbexa	100 tests	577.2 EUR
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (RPE)
abx415436-100tests	Abbexa	100 tests	710.4 EUR
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (RPE)
abx413475-100tests	Abbexa	100 tests	710.4 EUR
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (APC)
abx200527-100tests	Abbexa	100 tests	760.8 EUR
E. coli 0157:H7 antibody (HRP)
60-E07	Fitzgerald	100 ug	619.2 EUR
Description: Goat polyclonal E. coli 0157:H7 antibody (HRP) conjugated
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PerCP)
abx140293-100tests	Abbexa	100 tests	577.2 EUR
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (FITC)
abx415435-01mg	Abbexa	0.1 mg	610.8 EUR
HLA-DR Antigens-Associated Invariant Chain (HLA-DR) Antibody (PerCP)
abx200528-100tests	Abbexa	100 tests	543.6 EUR
Escherichia coli Serotype O15 (E. coli O15) Antibody
abx411331-02mg	Abbexa	0.2 mg	678 EUR
Escherichia coli Serotype O20 (E. coli O20) Antibody
abx411332-02mg	Abbexa	0.2 mg	678 EUR
E. coli 0157:H7 antibody (FITC)
60-E08	Fitzgerald	500 ug	676.8 EUR
Description: Goat polyclonal E. coli 0157:H7 antibody (FITC) conjugated
E. coli Enterotoxin LT Antibody
abx023834-1mg	Abbexa	1 mg	878.4 EUR
E. coli Enterotoxin LT Antibody
abx023835-1mg	Abbexa	1 mg	878.4 EUR
E. coli Enterotoxin LT Antibody
abx023836-1mg	Abbexa	1 mg	878.4 EUR
E. coli Enterotoxin LT Antibody
abx023837-1mg	Abbexa	1 mg	878.4 EUR
E. coli Enterotoxin B Antibody
abx021678-1mg	Abbexa	1 mg	718.8 EUR
E. coli Enterotoxin B Antibody
abx021679-1mg	Abbexa	1 mg	727.2 EUR
E. coli Enterotoxin B Antibody
abx021680-1mg	Abbexa	1 mg	718.8 EUR
E. coli Glycerol Kinase Antibody
32699-05111	AssayPro	150 ug	313.2 EUR
E. coli Enterotoxin STp Antibody
abx023838-1mg	Abbexa	1 mg	1053.6 EUR
E. coli Enterotoxin STp Antibody
abx023839-1mg	Abbexa	1 mg	1053.6 EUR
E. coli Enterotoxin STp Antibody
abx023840-1mg	Abbexa	1 mg	1053.6 EUR
E. coli Tryptophanase (Tnase) Antibody
33517-05111	AssayPro	150 ug	313.2 EUR
Escherichia coli 987P Pili (E. coli 987P Pilus) Antibody
abx411323-1ml	Abbexa	1 ml	610.8 EUR
Rabbit Anti-Borrelia burgdorferi (whole antigens) IgG
BBA12-A	Alpha Diagnostics	100 ul	562.8 EUR

×

The positivity of DSAs after pediatric liver transplantation was intently associated to the incidence of AMR. These outcomes prompt that DSAs needs to be routinely monitored post-operatively, and that DSA-positive recipients needs to be screened as quickly as attainable and given acceptable therapy.